Moderna shares are trading lower after Piper Sandler maintained an Overweight rating on the stock but lowered its price target from $157 to $115. Also, Oppenheimer downgraded the stock from Outperform to Perform.
Author: Benzinga Newsdesk | September 13, 2024 07:41am